Ko Kudo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ko Kudo has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
- Kiminori Terui
Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
9 shared publications - Etsuro Ito
Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
8 shared publications Shinya Sasaki
Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
7 shared publicationsAkie Kobayashi
Department of Pediatrics Hirosaki University Graduate School of Medicine Hirosaki Japan
6 shared publicationsRika Kanezaki
Department of Pediatrics Hirosaki University Graduate School of Medicine Hirosaki Japan
6 shared publicationsTakuya Kamio
Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
6 shared publications
Latest Publications
- Open Access
- 7 May 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (4)
Functional characterization of Griscelli syndrome type 2 sine albinism in Japanese patients
Griscelli syndrome type 2 (GS2), caused by biallelic RAB27A variants, is classically associated with hypopigmentation and life-threatening hemophagocytic lymphohistiocytosis (HLH). However, a few patients exhibit normal pigmentation, termed GS2 sine albinism. We identified two unrelated Japanese patients with this presentation caused by compound heterozygous RAB27A variants, representing the first functionally characterized cases among Japanese patients. Functional studies were performed using RAB27A-null cell systems to evaluate the two allele pairs: p.Trp73Arg/p.Val143Ala (patient 1) and p.Ser106PhefsTer18/p.Ser115Arg (patient 2). The truncating allele p.Ser106PhefsTer18 and the missense allele p.Trp73Arg failed to restore peripheral melanosome distribution and lost binding to both melanophilin (MLPH) and MUNC13-4. In contrast, p.Val143Ala and p.Ser115Arg preserved MLPH interaction but showed reduced binding to MUNC13-4. These findings demonstrate that RAB27A variants can dissociate melanosome transport from immune effector function in an allele-dependent manner. Importantly, the absence of hypopigmentation does not exclude GS2. Combined genetic and functional analyses are essential for precise variant interpretation and for guiding timely curative intervention in GS2.
- 7 May 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (4)
Open AccessFunctional characterization of Griscelli syndrome type 2 sine albinism in Japanese patients
Griscelli syndrome type 2 (GS2), caused by biallelic RAB27A variants, is classically associated with hypopigmentation and life-threatening hemophagocytic lymphohistiocytosis (HLH). However, a few patients exhibit normal pigmentation, termed GS2 sine albinism. We identified two unrelated Japanese patients with this presentation caused by compound heterozygous RAB27A variants, representing the first functionally characterized cases among Japanese patients. Functional studies were performed using RAB27A-null cell systems to evaluate the two allele pairs: p.Trp73Arg/p.Val143Ala (patient 1) and p.Ser106PhefsTer18/p.Ser115Arg (patient 2). The truncating allele p.Ser106PhefsTer18 and the missense allele p.Trp73Arg failed to restore peripheral melanosome distribution and lost binding to both melanophilin (MLPH) and MUNC13-4. In contrast, p.Val143Ala and p.Ser115Arg preserved MLPH interaction but showed reduced binding to MUNC13-4. These findings demonstrate that RAB27A variants can dissociate melanosome transport from immune effector function in an allele-dependent manner. Importantly, the absence of hypopigmentation does not exclude GS2. Combined genetic and functional analyses are essential for precise variant interpretation and for guiding timely curative intervention in GS2.
- Open Access
- 29 April 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (7) , 1427-1438
Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance
Minimally differentiated acute myeloid leukemia (AML-M0) is a rare and therapeutically challenging subgroup of AML characterized by immature hematopoietic stem cell-like features. To uncover the molecular basis, we conducted a comprehensive multi-omics analysis of 23 pediatric AML-M0 cases and compared them with 1483 leukemia samples. AML-M0 formed a characteristic group that exhibited global DNA hypermethylation and transcriptional suppression, particularly downregulation of genes related to oxidative phosphorylation and ribosome assembly compared to non-M0 AML. Genomic profiling revealed frequent loss-of-function alterations in RUNX1 (26%) and ETV6 (22%), along with activating mutations in signaling pathways (83%), such as RAS , FLT3 , and JAK . Notably, RUNX1 alterations were significantly associated with a poor prognosis. Functional analyses using a CRISPR/Cas9-mediated RUNX1 knockout in a pediatric AML-M0 cell line showed stem cell-like transcriptional features and reduced expression of genes related to oxidative phosphorylation and ribosomal pathways. RUNX1 disruption was also associated with reduced in vitro sensitivity to multiple drugs, including cytarabine and anthracyclines. Our study provides the most comprehensive molecular characterization of pediatric AML-M0 to date and identifies RUNX1 alterations as important biological and clinical determinants. These insights highlight the potential strategies for precision therapy, including hypomethylating agents, signaling inhibitors, and metabolic targeting, to improve outcomes.
- 29 April 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (7) , 1427-1438
Open AccessMulti-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance
Minimally differentiated acute myeloid leukemia (AML-M0) is a rare and therapeutically challenging subgroup of AML characterized by immature hematopoietic stem cell-like features. To uncover the molecular basis, we conducted a comprehensive multi-omics analysis of 23 pediatric AML-M0 cases and compared them with 1483 leukemia samples. AML-M0 formed a characteristic group that exhibited global DNA hypermethylation and transcriptional suppression, particularly downregulation of genes related to oxidative phosphorylation and ribosome assembly compared to non-M0 AML. Genomic profiling revealed frequent loss-of-function alterations in RUNX1 (26%) and ETV6 (22%), along with activating mutations in signaling pathways (83%), such as RAS , FLT3 , and JAK . Notably, RUNX1 alterations were significantly associated with a poor prognosis. Functional analyses using a CRISPR/Cas9-mediated RUNX1 knockout in a pediatric AML-M0 cell line showed stem cell-like transcriptional features and reduced expression of genes related to oxidative phosphorylation and ribosomal pathways. RUNX1 disruption was also associated with reduced in vitro sensitivity to multiple drugs, including cytarabine and anthracyclines. Our study provides the most comprehensive molecular characterization of pediatric AML-M0 to date and identifies RUNX1 alterations as important biological and clinical determinants. These insights highlight the potential strategies for precision therapy, including hypomethylating agents, signaling inhibitors, and metabolic targeting, to improve outcomes.
- 15 March 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (5) , e70236
Concurrent Somatic Mutations of the SETBP1 and KRAS Genes in Pediatric AML: A Case Report
- 15 March 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (5) , e70236
Concurrent Somatic Mutations of the SETBP1 and KRAS Genes in Pediatric AML: A Case Report
- 22 December 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (2) , e70034
Combination Therapy With Dabrafenib and Trametinib for Langerhans Cell Histiocytosis‐Associated Neurodegenerative Disease
- 22 December 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (2) , e70034
Combination Therapy With Dabrafenib and Trametinib for Langerhans Cell Histiocytosis‐Associated Neurodegenerative Disease
- Open Access
Phase II study in children and adults under 40 years with newly diagnosed Langerhans cell histiocytosis: protocol for an LCH-19-MSMFB clinical trial in Japan
Introduction Although the prognosis of Langerhans cell histiocytosis (LCH) is excellent, the high recurrence rate and permanent consequences, such as central diabetes insipidus and LCH-associated neurodegenerative diseases, remain to be resolved. Based on previous reports that patients with high-risk multisystem LCH show elevated levels of inflammatory molecules, we hypothesised that dexamethasone would more effectively suppress LCH-associated inflammation, especially in the central nervous system (CNS). We further hypothesised that intrathecal chemotherapy would effectively reduce CNS complications. We administer zoledronate to patients with multifocal bone LCH based on an efficacy report from a small case series. Methods and analysis This phase II study (labelled the LCH-19-MSMFB study) is designed to evaluate the significance of introducing dexamethasone and intrathecal chemotherapy for multisystem disease and zoledronate for multifocal bone disease in previously untreated, newly diagnosed children, adolescents (under 20 years) and adults under 40 years. The primary endpoint is the 3-year event-free survival rate by risk group of under 20 years and the 3-year event-free survival rate of 20 years and over. Ethics and dissemination This study was approved by the Central Review Board of the National Hospital Organisation Nagoya Medical Centre (Nagoya, Japan) on 21 January 2022 and was registered in the Japan Registry of Clinical Trials (https://jrct.niph.go.jp/en-latest-detail/jRCTs041210027). Written informed consent will be obtained from all patients and/or their guardians. Trial registration number jRCTs041210027.
Open AccessPhase II study in children and adults under 40 years with newly diagnosed Langerhans cell histiocytosis: protocol for an LCH-19-MSMFB clinical trial in Japan
Introduction Although the prognosis of Langerhans cell histiocytosis (LCH) is excellent, the high recurrence rate and permanent consequences, such as central diabetes insipidus and LCH-associated neurodegenerative diseases, remain to be resolved. Based on previous reports that patients with high-risk multisystem LCH show elevated levels of inflammatory molecules, we hypothesised that dexamethasone would more effectively suppress LCH-associated inflammation, especially in the central nervous system (CNS). We further hypothesised that intrathecal chemotherapy would effectively reduce CNS complications. We administer zoledronate to patients with multifocal bone LCH based on an efficacy report from a small case series. Methods and analysis This phase II study (labelled the LCH-19-MSMFB study) is designed to evaluate the significance of introducing dexamethasone and intrathecal chemotherapy for multisystem disease and zoledronate for multifocal bone disease in previously untreated, newly diagnosed children, adolescents (under 20 years) and adults under 40 years. The primary endpoint is the 3-year event-free survival rate by risk group of under 20 years and the 3-year event-free survival rate of 20 years and over. Ethics and dissemination This study was approved by the Central Review Board of the National Hospital Organisation Nagoya Medical Centre (Nagoya, Japan) on 21 January 2022 and was registered in the Japan Registry of Clinical Trials (https://jrct.niph.go.jp/en-latest-detail/jRCTs041210027). Written informed consent will be obtained from all patients and/or their guardians. Trial registration number jRCTs041210027.
- 20 June 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (25) , 2627-2643
Landscape of driver mutations and their clinical effects on Down syndrome–related myeloid neoplasms
Transient abnormal myelopoiesis (TAM) is a common complication in newborns with Down syndrome (DS). It commonly progresses to myeloid leukemia (ML-DS) after spontaneous regression. In contrast to the favorable prognosis of primary ML-DS, patients with refractory/relapsed ML-DS have poor outcomes. However, the molecular basis for refractoriness and relapse and the full spectrum of driver mutations in ML-DS remain largely unknown. We conducted a genomic profiling study of 143 TAM, 204 ML-DS, and 34 non-DS acute megakaryoblastic leukemia cases, including 39 ML-DS cases analyzed by exome sequencing. Sixteen novel mutational targets were identified in ML-DS samples. Of these, inactivations of IRX1 (16.2%) and ZBTB7A (13.2%) were commonly implicated in the upregulation of the MYC pathway and were potential targets for ML-DS treatment with bromodomain-containing protein 4 inhibitors. Partial tandem duplications of RUNX1 on chromosome 21 were also found, specifically in ML-DS samples (13.7%), presenting its essential role in DS leukemia progression. Finally, in 177 patients with ML-DS treated following the same ML-DS protocol (the Japanese Pediatric Leukemia and Lymphoma Study Group acute myeloid leukemia -D05/D11), CDKN2A, TP53, ZBTB7A, and JAK2 alterations were associated with a poor prognosis. Patients with CDKN2A deletions (n = 7) or TP53 mutations (n = 4) had substantially lower 3-year event-free survival (28.6% vs 90.5%; P < .001; 25.0% vs 89.5%; P < .001) than those without these mutations. These findings considerably change the mutational landscape of ML-DS, provide new insights into the mechanisms of progression from TAM to ML-DS, and help identify new therapeutic targets and strategies for ML-DS.
- 20 June 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (25) , 2627-2643
Landscape of driver mutations and their clinical effects on Down syndrome–related myeloid neoplasms
Transient abnormal myelopoiesis (TAM) is a common complication in newborns with Down syndrome (DS). It commonly progresses to myeloid leukemia (ML-DS) after spontaneous regression. In contrast to the favorable prognosis of primary ML-DS, patients with refractory/relapsed ML-DS have poor outcomes. However, the molecular basis for refractoriness and relapse and the full spectrum of driver mutations in ML-DS remain largely unknown. We conducted a genomic profiling study of 143 TAM, 204 ML-DS, and 34 non-DS acute megakaryoblastic leukemia cases, including 39 ML-DS cases analyzed by exome sequencing. Sixteen novel mutational targets were identified in ML-DS samples. Of these, inactivations of IRX1 (16.2%) and ZBTB7A (13.2%) were commonly implicated in the upregulation of the MYC pathway and were potential targets for ML-DS treatment with bromodomain-containing protein 4 inhibitors. Partial tandem duplications of RUNX1 on chromosome 21 were also found, specifically in ML-DS samples (13.7%), presenting its essential role in DS leukemia progression. Finally, in 177 patients with ML-DS treated following the same ML-DS protocol (the Japanese Pediatric Leukemia and Lymphoma Study Group acute myeloid leukemia -D05/D11), CDKN2A, TP53, ZBTB7A, and JAK2 alterations were associated with a poor prognosis. Patients with CDKN2A deletions (n = 7) or TP53 mutations (n = 4) had substantially lower 3-year event-free survival (28.6% vs 90.5%; P < .001; 25.0% vs 89.5%; P < .001) than those without these mutations. These findings considerably change the mutational landscape of ML-DS, provide new insights into the mechanisms of progression from TAM to ML-DS, and help identify new therapeutic targets and strategies for ML-DS.
- 28 April 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (7) , e31043
Juvenile xanthogranuloma manifesting with LCH‐associated neurodegenerative disease‐like radiological findings
Here, we describe two patients with juvenile xanthogranuloma (JXG) manifesting with Langerhans cell histiocytosis (LCH)‐associated neurodegenerative disease (ND)‐like radiological findings. One patient showed typical radiological abnormalities at onset, which worsened with progressing central nervous system symptoms 7 years after LCH‐oriented chemotherapy. Another showed spontaneous regression of clinical symptoms, with a transient radiological change 1 year after salvage chemotherapy for recurrence of JXG. These data regarding JXG‐associated ND will facilitate future investigation of the disease, as well as development of therapeutic interventions.
- 28 April 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (7) , e31043
Juvenile xanthogranuloma manifesting with LCH‐associated neurodegenerative disease‐like radiological findings
Here, we describe two patients with juvenile xanthogranuloma (JXG) manifesting with Langerhans cell histiocytosis (LCH)‐associated neurodegenerative disease (ND)‐like radiological findings. One patient showed typical radiological abnormalities at onset, which worsened with progressing central nervous system symptoms 7 years after LCH‐oriented chemotherapy. Another showed spontaneous regression of clinical symptoms, with a transient radiological change 1 year after salvage chemotherapy for recurrence of JXG. These data regarding JXG‐associated ND will facilitate future investigation of the disease, as well as development of therapeutic interventions.
- Open Access
- 6 April 2024
- Published by Wiley
Juvenile xanthogranuloma manifesting with LCH-associated neurodegenerative disease-like radiological findings
Here, we describe two patients with juvenile xanthogranuloma (JXG) manifesting with Langerhans cell histiocytosis-associated neurodegenerative disease (ND)-like radiological findings. One patient showed typical radiological abnormalities at onset, which worsened with progressing central nervous system symptoms 7 years after LCH-oriented chemotherapy. Another showed spontaneous regression of clinical symptoms, with a transient radiological change 1 year after salvage chemotherapy for recurrence of JXG. These data regarding JXG-associated ND will facilitate future investigation of the disease, as well as development of therapeutic interventions.
- 6 April 2024
- Published by Wiley
Open AccessJuvenile xanthogranuloma manifesting with LCH-associated neurodegenerative disease-like radiological findings
Here, we describe two patients with juvenile xanthogranuloma (JXG) manifesting with Langerhans cell histiocytosis-associated neurodegenerative disease (ND)-like radiological findings. One patient showed typical radiological abnormalities at onset, which worsened with progressing central nervous system symptoms 7 years after LCH-oriented chemotherapy. Another showed spontaneous regression of clinical symptoms, with a transient radiological change 1 year after salvage chemotherapy for recurrence of JXG. These data regarding JXG-associated ND will facilitate future investigation of the disease, as well as development of therapeutic interventions.
- 27 December 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (3) , e30834
Transient erythroblastopenia due to a GATA1 variant in an infant female
Diamond–Blackfan anemia (DBA) is a congenital anemia with erythroid cell aplasia. Most of the causative genes are ribosomal proteins. GATA1, a hematopoietic master transcription factor required for erythropoiesis, also causes DBA. GATA1 is located on Xp11.23; therefore, DBA develops only in males in an X‐linked inheritance pattern. Here, we report a case of transient erythroblastopenia and moderate anemia in a female newborn infant with a de novo GATA1 variant. In this patient, increased methylation of the GATA1 wild‐type allele was observed in erythroid cells. Skewed lyonization of GATA1 may cause mild transient erythroblastopenia in a female patient.
- 27 December 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (3) , e30834
Transient erythroblastopenia due to a GATA1 variant in an infant female
Diamond–Blackfan anemia (DBA) is a congenital anemia with erythroid cell aplasia. Most of the causative genes are ribosomal proteins. GATA1, a hematopoietic master transcription factor required for erythropoiesis, also causes DBA. GATA1 is located on Xp11.23; therefore, DBA develops only in males in an X‐linked inheritance pattern. Here, we report a case of transient erythroblastopenia and moderate anemia in a female newborn infant with a de novo GATA1 variant. In this patient, increased methylation of the GATA1 wild‐type allele was observed in erythroid cells. Skewed lyonization of GATA1 may cause mild transient erythroblastopenia in a female patient.
- 5 October 2022
- Published by Springer Nature in Annals of Hematology
- Vol. 101 (12) , 2803-2804
Preceding polydipsia/polyuria, ataxia, and dysarthria in an adult with mixed histiocytosis (Erdheim Chester disease/Langerhans cell histiocytosis)
- 5 October 2022
- Published by Springer Nature in Annals of Hematology
- Vol. 101 (12) , 2803-2804
Preceding polydipsia/polyuria, ataxia, and dysarthria in an adult with mixed histiocytosis (Erdheim Chester disease/Langerhans cell histiocytosis)